Home › Funds › BAKER BROS. ADVISORS LP › RYTM

BAKER BROS. ADVISORS LP position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 5,604,483 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$622.3M, representing 3.25% of its reported portfolio and ranking #9 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.60M sh
Reported value held$622.27M
Portfolio Weight3.25%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's RYTM position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in RYTM in Q3 2023 at 6,702,349 shares (US$153.7M). The position peaked in Q2 2026 at 5,604,483 shares, worth US$622.3M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 5,604,483 shares valued at US$622.3M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.70M $153.65M New
Q4 2023 6.40M $294.13M Reduce
Q1 2024 6.40M $277.24M Hold
Q2 2024 6.40M $262.72M Hold
Q3 2024 6.40M $335.21M Hold
Q4 2024 6.08M $340.60M Reduce
Q1 2025 5.60M $296.87M Reduce
Q2 2025 5.60M $354.15M Hold
Q3 2025 5.60M $566.00M Hold
Q4 2025 5.60M $599.90M Hold
Q1 2026 5.60M $487.42M Hold
Q2 2026 5.60M $622.27M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), PERCEPTIVE ADVISORS LLC (US$287.2M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$245.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held RYTM?

BAKER BROS. ADVISORS LP has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in RYTM?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 5.60M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $622.27M, representing 3.25% of its reported portfolio and ranking #9.

Has BAKER BROS. ADVISORS LP been buying or selling RYTM?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in RYTM. The position peaked in Q2 2026 at 5.60M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, WESTFIELD CAPITAL MANAGEMENT CO LP, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.